Richard A. Van Etten

19.9k total citations · 6 hit papers
144 papers, 15.1k citations indexed

About

Richard A. Van Etten is a scholar working on Hematology, Genetics and Molecular Biology. According to data from OpenAlex, Richard A. Van Etten has authored 144 papers receiving a total of 15.1k indexed citations (citations by other indexed papers that have themselves been cited), including 112 papers in Hematology, 71 papers in Genetics and 38 papers in Molecular Biology. Recurrent topics in Richard A. Van Etten's work include Chronic Myeloid Leukemia Treatments (102 papers), Chronic Lymphocytic Leukemia Research (45 papers) and Eosinophilic Disorders and Syndromes (37 papers). Richard A. Van Etten is often cited by papers focused on Chronic Myeloid Leukemia Treatments (102 papers), Chronic Lymphocytic Leukemia Research (45 papers) and Eosinophilic Disorders and Syndromes (37 papers). Richard A. Van Etten collaborates with scholars based in United States, Germany and United Kingdom. Richard A. Van Etten's co-authors include Daniela S. Krause, David Baltimore, George Q. Daley, David A. Clayton, Robert Ilaria, Mark W. Walberg, Maureen J. Bibb, Peter K. Jackson, Thomas Force and Shaoguang Li and has published in prestigious journals such as Nature, Science and New England Journal of Medicine.

In The Last Decade

Richard A. Van Etten

139 papers receiving 14.7k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Induction of Chronic Myelogenous Leukemia in Mice by the P210 ^bcr/abl Gene of the Philadelphia Chromosome

1990 1.7k citations George Q. Daley, Richard A. Van Etten et al. profile →
Sequence and gene organization of mouse mitochondrial DNA

1981 1.5k citations Maureen J. Bibb, Richard A. Van Etten et al. profile →
Tyrosine Kinases as Targets for Cancer Therapy

2005 1.1k citations Daniela S. Krause, Richard A. Van Etten profile →
Cardiotoxicity of the cancer therapeutic agent imatinib mesylate

2006 858 citations Risto Kerkelä, Luanda Grazette et al. Nature Medicine profile →
Essential role for the peroxiredoxin Prdx1 in erythrocyte antioxidant defence and tumour suppression

2003 659 citations Daniela S. Krause, Richard A. Van Etten et al. profile →
Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition

2007 604 citations Thomas Force, Daniela S. Krause et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Richard A. Van Etten United States	51	7.0k	6.9k	4.3k	3.3k	2.2k	144	15.1k
D. Gary Gilliland United States	62	8.4k 1.2×	8.1k 1.2×	4.2k 1.0×	2.8k 0.8×	2.0k 0.9×	126	16.2k
Herbert Y. Lin United States	55	6.5k 0.9×	4.1k 0.6×	3.0k 0.7×	1.3k 0.4×	665 0.3×	110	13.7k
Roland Berger France	68	10.2k 1.5×	9.2k 1.3×	4.7k 1.1×	3.0k 0.9×	1.5k 0.7×	356	18.7k
Bruno Calabretta United States	65	8.6k 1.2×	3.4k 0.5×	1.9k 0.4×	2.6k 0.8×	723 0.3×	237	13.2k
Richard M. Lawn United States	60	7.5k 1.1×	3.6k 0.5×	1.6k 0.4×	1.9k 0.6×	571 0.3×	104	16.4k
Emmanuelle Passegué United States	54	7.8k 1.1×	5.5k 0.8×	2.1k 0.5×	3.0k 0.9×	292 0.1×	98	15.3k
Olli Silvennoinen Finland	63	7.0k 1.0×	1.5k 0.2×	2.0k 0.5×	8.5k 2.6×	974 0.4×	159	16.7k
Fumio Arai Japan	37	4.6k 0.7×	3.6k 0.5×	1.8k 0.4×	2.0k 0.6×	261 0.1×	98	9.2k
Stephen D. Nimer United States	64	7.5k 1.1×	6.8k 1.0×	2.8k 0.6×	3.4k 1.0×	246 0.1×	239	14.6k
Martin J.S. Dyer United Kingdom	71	6.3k 0.9×	2.1k 0.3×	6.1k 1.4×	4.6k 1.4×	190 0.1×	300	16.5k

Countries citing papers authored by Richard A. Van Etten

Since Specialization

Citations

This map shows the geographic impact of Richard A. Van Etten's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Richard A. Van Etten with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Richard A. Van Etten more than expected).

Fields of papers citing papers by Richard A. Van Etten

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Richard A. Van Etten. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Richard A. Van Etten. The network helps show where Richard A. Van Etten may publish in the future.

Co-authorship network of co-authors of Richard A. Van Etten

This figure shows the co-authorship network connecting the top 25 collaborators of Richard A. Van Etten. A scholar is included among the top collaborators of Richard A. Van Etten based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Richard A. Van Etten. Richard A. Van Etten is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kongtim, Piyanuch, et al.. (2025). Budesonide, Added to PTCy‐Based Regimen, for Prevention of Acute GI GVHD After Allogeneic Stem Cell Transplantation. American Journal of Hematology. 100(3). 383–392.

Jena, Nilamani, et al.. (2023). Predictive nonlinear modeling of malignant myelopoiesis and tyrosine kinase inhibitor therapy. eLife. 12. 4 indexed citations

Jeyakumar, Deepa, et al.. (2023). Budesonide Added to Post-Transplantation Cyclophosphamide, Tacrolimus and Mycophenolate Mofetil for Prevention of Graft-Versus-Host Disease. Blood. 142(Supplement 1). 2192–2192.

Gohil, Shruti K., Thomas Tjoa, Hiroki Saito, et al.. (2022). 1668. The SAFER Lines Project: A Mobile-App Strategy for Prevention of Outpatient Central Line Associated Bloodstream Infection (CLABSI). Open Forum Infectious Diseases. 9(Supplement_2).

Mughal, Tariq I., Bethan Psaila, Daniel J. DeAngelo, et al.. (2021). Interrogating the molecular genetics of chronic myeloproliferative malignancies for personalized management in 2021. Haematologica. 106(7). 1787–1793. 4 indexed citations

Mughal, Tariq I., Naveen Pemmaraju, Bethan Psaila, et al.. (2020). Illuminating novel biological aspects and potential new therapeutic approaches for chronic myeloproliferative malignancies. Hematological Oncology. 38(5). 654–664. 1 indexed citations

Kumar, Rahul, Raquel Pereira, Valentina R. Minciacchi, et al.. (2020). Specific, targetable interactions with the microenvironment influence imatinib-resistant chronic myeloid leukemia. Leukemia. 34(8). 2087–2101. 29 indexed citations

Mughal, Tariq I., Omar Abdel‐Wahab, Raajit K. Rampal, et al.. (2016). Contemporary insights into the pathogenesis and treatment of chronic myeloproliferative neoplasms. Leukemia & lymphoma. 57(7). 1517–1526. 6 indexed citations

Joshi, Ila, Toshimi Yoshida, Nilamani Jena, et al.. (2014). Loss of Ikaros DNA-binding function confers integrin-dependent survival on pre-B cells and progression to acute lymphoblastic leukemia. Nature Immunology. 15(3). 294–304. 112 indexed citations

10.

Etten, Richard A. Van. (2013). New insights into the normal and leukemic stem cell niche: A timely review. Cytometry Part B Clinical Cytometry. 84B(1). 5–6. 5 indexed citations

11.

Okimoto, Ross A. & Richard A. Van Etten. (2011). Navigating the road toward optimal initial therapy for chronic myeloid leukemia. Current Opinion in Hematology. 18(2). 89–97. 19 indexed citations

12.

Krause, Daniela S. & Richard A. Van Etten. (2007). Right on target: eradicating leukemic stem cells. Trends in Molecular Medicine. 13(11). 470–481. 103 indexed citations

13.

Kerkelä, Risto, Luanda Grazette, Rinat Yacobi, et al.. (2006). Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nature Medicine. 12(8). 908–916. 858 indexed citations breakdown →

14.

Derkinderen, Pascal, Timothy M.E. Scales, Diane P. Hanger, et al.. (2005). Tyrosine 394 Is Phosphorylated in Alzheimer's Paired Helical Filament Tau and in Fetal Tau with c-Abl as the Candidate Tyrosine Kinase. Journal of Neuroscience. 25(28). 6584–6593. 153 indexed citations

15.

Etten, Richard A. Van & Kevin Shannon. (2004). Focus on myeloproliferative diseases and myelodysplastic syndromes. Cancer Cell. 6(6). 547–552. 67 indexed citations

16.

Etten, Richard A. Van. (2001). Pathogenesis and treatment of Ph+ leukemia: recent insights from mouse models. Current Opinion in Hematology. 8(4). 224–230. 11 indexed citations

17.

Liu, Liqin, Robert Ilaria, Paul D. Kingsley, et al.. (1999). A Novel Ubiquitin-Specific Protease, UBP43, Cloned from Leukemia Fusion Protein AML1-ETO-Expressing Mice, Functions in Hematopoietic Cell Differentiation. Molecular and Cellular Biology. 19(4). 3029–3038. 130 indexed citations

18.

Schwaller, Juerg, Julie Frantsve‐Hawley, Jon C. Aster, et al.. (1998). Transformation of hematopoietic cell lines to growth-factor independence and induction of a fatal myelo- and lymphoproliferative disease in mice by retrovirally transduced TEL/JAK2 fusion genes. The EMBO Journal. 17(18). 5321–5333. 213 indexed citations

19.

Daley, George Q., Richard A. Van Etten, Peter K. Jackson, André Bernards, & David Baltimore. (1992). Nonmyristoylated Abl Proteins Transform a Factor-Dependent Hematopoietic Cell Line. Molecular and Cellular Biology. 12(4). 1864–1871. 18 indexed citations

20.

Etten, Richard A. Van, Nelson L. Michael, Maureen J. Bibb, Axel Brennicke, & David A. Clayton. (1982). Expression of the Mouse Mitochondrial DNA Genome. Cold Spring Harbor Monograph Archive. 12. 73–88. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact